Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying blood and tumor tissue samples from young patients with acute myeloid leukemia.
Genetic: gene expression analysis
Genetic: western blotting
Other: flow cytometry
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples|
- Expression of Mer and Axl [ Designated as safety issue: No ]
- Association of abnormal expression of Mer and Axl with induction failure or relapse [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
blood and tumor samples
|Study Start Date:||September 2009|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
- To evaluate Mer and Axl expression in samples from pediatric patients with acute myeloid leukemia (AML).
- To determine if abnormal expression of Mer and Axl is associated with poor clinical characteristics (e.g., induction failure or relapse) of AML in these patients.
OUTLINE: This is a multicenter study.
Archived samples from pediatric patients with acute myeloid leukemia are analyzed for Mer and Axl expression by flow cytometry and western blot assays.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01139333
|Principal Investigator:||Kristen M. Eisenman, MD||University of Colorado, Denver|